1-7 of 7
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
MinuteCE®Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
MinuteCE®Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
MinuteCE®Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
MinuteCE®Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Jenny Seligmann, MBChB, PhD
Fortunato Ciardiello, MD, PhD
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
From Guidelines to Practice: First-Line Treatment Choices in mCRC
MinuteCE®From Guidelines to Practice: First-Line Treatment Choices in mCRC
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
- advertisement
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
MinuteCE®Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD